Integrative pan-cancer genomics reveals immune-inflammatory associations of FES and its potential therapeutic relevance in gastric cancer

Introduction FES encodes a non‐receptor tyrosine kinase with context‐dependent functions in cancer; however, its cross‐cancer genomic landscape, immune microenvironmental relevance, and therapeutic implications remain incompletely defined. We therefore characterized FES across cancers and validated its functional and therapeutic relevance experimentally. Methods We integrated transcriptomic, genomic, clinical, pharmacogenomic, immunogenomic, and spatial transcriptomic datasets from TCGA, GTEx, GEO, GDSC, the Connectivity Map, and public spatial transcriptomic resources. Experimental validation was performed in gastric cancer cell lines HGC‐27 and AGS using shRNA‐mediated FES knockdown, qRT‐PCR, cell viability and Transwell migration assays under four conditions (sh‐NC, sh‐FES, imatinib, and sh‐FES plus imatinib), followed by validation in a nude mouse xenograft model. Results FES showed marked cancer type‐specific dysregulation, being downregulated in several epithelial malignancies but upregulated in kidney renal clear cell carcinoma and stomach adenocarcinoma, while overall mutation frequency remained low. FES showed strong diagnostic discrimination in multiple cancers and was associated with unfavorable survival in lower‐grade glioma, glioblastoma, colon adenocarcinoma, and stomach adenocarcinoma. Systems-level analyses linked high FES expression to epithelial–mesenchymal transition, angiogenesis, inflammatory response, and IL6/JAK/STAT3 signaling. FES was broadly and positively correlated with chemokines, immune checkpoint molecules, MHC‐related genes, and infiltration of macrophages, dendritic cells, fibroblasts, and endothelial cells. Spatial transcriptomic analysis localized FES expression to immune‐ and stromal‐enriched tumor regions, and pharmacogenomic analyses nominated imatinib as a candidate compound capable of reversing the FES-related expression signature. Experimentally, FES knockdown reduced FES mRNA expression, cell viability, migratory capacity, and xenograft growth. Imatinib produced additional inhibitory effects, and the combined intervention consistently showed the strongest suppression in vitro and in vivo . Discussion These findings suggest that FES expression is associated with immune‐inflammatory features across cancer types and highlight its potential therapeutic relevance in gastric cancer. The convergence of pan‐cancer multi‐omics evidence with cellular and animal validation supports further investigation of FES for tumor stratification and therapeutic targeting, particularly in gastric cancer.

Authors

Institutions

Publication Details

Journal
Frontiers in Cell and Developmental Biology
Published
2026-11-17
DOI
https://doi.org/10.3389/fcell.2026.1974616
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrative pan-cancer genomics reveals immune-inflammatory associations of FES and its potential therapeutic relevance in gastric cancer

Shuyu Zhai, Ningzhen Fu, Yuchen Ji, Zhichao Yao et al.
Frontiers in Cell and Developmental Biology
Cancer Immunotherapy and Biomarkers
article

Integrative pan-cancer genomics reveals immune-inflammatory associations of FES and its potential therapeutic relevance in gastric cancer

Shuyu Zhai, Ningzhen Fu, Yuchen Ji, Zhichao Yao, Junjie Xie, Shuyang Fan, Yunxiang Chen
article en

Abstract

Introduction FES encodes a non‐receptor tyrosine kinase with context‐dependent functions in cancer; however, its cross‐cancer genomic landscape, immune microenvironmental relevance, and therapeutic implications remain incompletely defined. We therefore characterized FES across cancers and validated its functional and therapeutic relevance experimentally. Methods We integrated transcriptomic, genomic, clinical, pharmacogenomic, immunogenomic, and spatial transcriptomic datasets from TCGA, GTEx, GEO, GDSC, the Connectivity Map, and public spatial transcriptomic resources. Experimental validation was performed in gastric cancer cell lines HGC‐27 and AGS using shRNA‐mediated FES knockdown, qRT‐PCR, cell viability and Transwell migration assays under four conditions (sh‐NC, sh‐FES, imatinib, and sh‐FES plus imatinib), followed by validation in a nude mouse xenograft model. Results FES showed marked cancer type‐specific dysregulation, being downregulated in several epithelial malignancies but upregulated in kidney renal clear cell carcinoma and stomach adenocarcinoma, while overall mutation frequency remained low. FES showed strong diagnostic discrimination in multiple cancers and was associated with unfavorable survival in lower‐grade glioma, glioblastoma, colon adenocarcinoma, and stomach adenocarcinoma. Systems-level analyses linked high FES expression to epithelial–mesenchymal transition, angiogenesis, inflammatory response, and IL6/JAK/STAT3 signaling. FES was broadly and positively correlated with chemokines, immune checkpoint molecules, MHC‐related genes, and infiltration of macrophages, dendritic cells, fibroblasts, and endothelial cells. Spatial transcriptomic analysis localized FES expression to immune‐ and stromal‐enriched tumor regions, and pharmacogenomic analyses nominated imatinib as a candidate compound capable of reversing the FES-related expression signature. Experimentally, FES knockdown reduced FES mRNA expression, cell viability, migratory capacity, and xenograft growth. Imatinib produced additional inhibitory effects, and the combined intervention consistently showed the strongest suppression in vitro and in vivo . Discussion These findings suggest that FES expression is associated with immune‐inflammatory features across cancer types and highlight its potential therapeutic relevance in gastric cancer. The convergence of pan‐cancer multi‐omics evidence with cellular and animal validation supports further investigation of FES for tumor stratification and therapeutic targeting, particularly in gastric cancer.

Frontiers in Cell and Developmental BiologyVol. 14
Shanghai Medical College of Fudan University (CN), Shanghai Jiao Tong University (CN), Fudan University (CN), Ruijin Hospital (CN), Huashan Hospital (CN), Jinhua Central Hospital (CN), Zhejiang University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon